What are the functions and effects of ribociclib? What diseases does it have significant efficacy in treating?

Ribociclib is a selective CDK4/6 inhibitor mainly used for treatment Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It can inhibit cyclin-dependent kinases 4 and 6 (CDK4/6), prevent excessive proliferation of cancer cells, and thereby slow down tumor progression. Ribociclib is often given in combination with endocrine therapy (such as letrozole or fulvestrant) to enhance the anticancer effect.

In clinical studies, ribociclib has shown the advantage of significantly extending progression-free survival (PFS). For example, the MONALEESA series of trials showed that in patients with HR+/HER2- metastatic breast cancer, ribociclib combined with an aromatase inhibitor or fulvestrant can reduce the risk of disease progression or death by about 40%-50% compared with endocrine therapy alone. Survival period was significantly prolonged. Therefore, it has become the standard first- or second-line treatment for HR+/HER2- breast cancer.

The efficacy of ribociclib is particularly suitable for premenopausal and postmenopausal female patients . It also shows good therapeutic effects in young breast cancer patients . In addition, research shows that ribociclib can not only significantly delay disease progression, but also improve patients' quality of life, reduce symptom exacerbation, and maintain disease stability for a longer period of time. For patients with a tendency for endocrine resistance, ribociclib combination therapy can still provide good clinical benefits.

Although ribociclib has significant efficacy, it may cause certain side effects, such as leukopenia, abnormal liver function, cardiotoxicity (QT interval prolongation), etc. Therefore, regular blood routine, liver function and electrocardiogram need to be monitored during the medication. Doctors usually adjust the dose or take corresponding management measures based on the patient's specific situation to reduce the impact of adverse reactions. Overall, ribociclib, as one of the representative drugs of CDK4/6 inhibitors, has become HR+/HER2-An important treatment option for metastatic breast cancer, providing patients with longer survival benefits and better quality of life.